Hikma Pharmaceuticals Public annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Debt-to-Equity Ratio Growth & History (HIK)
Hikma Pharmaceuticals Public's debt-to-equity ratio was 0.62 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.62 | 0.05 | +9.41% |
| 2024 | 2024-12-31 | 0.57 | 0.02 | +4.34% |
| 2023 | 2023-12-31 | 0.54 | −0.06 | −9.83% |
| 2022 | 2022-12-31 | 0.60 | 0.26 | +74.24% |
| 2021 | 2021-12-31 | 0.34 | −0.09 | −20.99% |
| 2020 | 2020-12-31 | 0.44 | — | — |
Hikma Pharmaceuticals Public quarterly debt-to-equity ratio
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.78 | 0.16 | +26.36% |
| Q4 2025 | 2025-12-31 | 0.62 | 0.05 | +9.41% |
| Q2 2025 | 2025-06-30 | 0.61 | — | — |
| Q4 2024 | 2024-12-31 | 0.57 | — | — |
Hikma Pharmaceuticals Public debt-to-equity ratio trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's debt-to-equity ratio increased from 0.44 to 0.62, a change of 0.18. The latest reported quarter, Q2 2026, shows 0.78.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...